Sandoz presented new mid-term targets and a long-term growth strategy for its biosimilars business during an investor day on Tuesday, setting out ambitions that would make biosimilars the majority contributor to revenue within the decade.
The company confirmed its existing goals through 2028, which call for a core EBITDA margin of 24 to 26 percent. It added a new target for 2030: mid-to-high single-digit annual revenue growth at constant exchange rates, alongside a core EBITDA margin of 25 to 27 percent.
Under the "Bio100" program, Sandoz aims to expand its biosimilars portfolio to more than 100 products by 2040, up from 13 currently. The company also said that by 2035, approximately 80 percent of biosimilars value will be covered by products facing upcoming patent expiries, compared with roughly 50 percent today.
Net revenue from biosimilars should more than double by 2035 relative to 2025 under the Bio100 plan, while the core EBITDA margin should rise above 30 percent, according to the company.
CEO Richard Saynor said Sandoz is entering its next growth phase, with biosimilars poised to become the majority share of revenue and broaden access to affordable medicines.
